Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: consensus recommendations (original) (raw)

Abstract

ype 1 Gaucher disease is the most common lysosomal storage disease and the most common genetic disorder among persons of Ashkenazi Jewish descent. It is caused by deficiency of the enzyme glucocerebrosidase, which is necessary for the intralysosomal catabolism of glucocerebroside (GC), and is inherited in an autosomal recessive fashion. 1,2 This results in accumulation of GC (most of which is derived from phagocytosed cell membranes) in the lysosomes of monocyte-derived macrophages in tissues of the reticuloendothelial system. 3,4 Accumulation in the Kupffer cells of the liver and in splenic macrophages is associated with enlargement of these organs. The resulting hypersplenism produces progressive anemia and thrombocytopenia. Accumulation of GC in bone marrow is associated with osteopenia, lytic lesions, pathologic fractures, chronic bone pain, acute episodes of excruciating ''bone crisis,'' bone infarcts, and osteonecrosis. Although anemia and thrombocytopenia may be severe, it is usually bone disease that results in the greatest morbidity and long-term disability. Type 1 Gaucher disease responds well to enzyme replacement therapy (ERT) with recombinant human macrophage-targeted recombinant human glucocerebrosidase (imiglucerase, Cerezyme, Genzyme Corporation, Cambridge, Mass). 5-7 Treatment results in breakdown of stored GC, reduction in liver and spleen size, amelioration or resolution of anemia and thrombocytopenia, decreased bone pain, and increased bone mineralization and remodeling over a period of several years. 7-9 Although type 1 Gaucher disease is often referred to as the ''adult type,'' the age of onset and rate of progression vary widely, and more than half of all patients are diagnosed before the age of 10 years. Among those diagnosed before age 10, 68% are diagnosed even before age five. 10 When children with type 1 Gaucher disease exhibit symptoms, the disease is more severe, requiring more frequent monitoring and early intervention. In addition to the effects of the disease described previously, children with type 1 Gaucher disease are frequently growth-restricted and have delayed onset of puberty; 50% of symptomatic children are at or below the third percentile for height, and another 25% are shorter than expected based on their midparental height. 11 The organomegaly is particularly noticeable in young children, who often have markedly protuberant abdomens. Chronic pain and fatigue may affect school performance and participation in physical activities. That children with type 1 Gaucher disease are different than adults with this disorder is also evident from the genotypes observed (Table I). Homozygosity for the N370S mutation, commonly found in mildly affected adults, is much less common in symptomatic children. In contrast, genotypes including the 84GG or L444P alleles, typically associated with more severe disease, are more common in patients who exhibit signs of Gaucher disease during childhood, than in patients who first exhibit symptoms later in life.

Figures (4)

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (72)

  1. Brady RO, Kanfer JN, Shapiro D. Metabolism of glucocerebrosides, II. Evidence of an enzymatic deficiency in Gaucher disease. Biochem Biophys Res Commun 1965;18:221-5.
  2. Patrick AD. Short communications: a deficiency of glucocerebrosidase in Gaucher disease. Biochem J 1965;97:17C-8C.
  3. Desnick RJ. Gaucher disease: a century of delineation and understand- ing. Prog Clin Biol Res 1982;95:1-30.
  4. Parkin JL, Brunning RD. Pathology of the Gaucher cell. Prog Clin Biol Res 1982;95:150-75.
  5. Grabowski GA, Barton NW, Pastores G, Dambrosia JM, Banerjee TK, McKee MA, et al. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombi- nant sources. Ann Intern Med 1995;122:33-9.
  6. Zimran A, Elstein D, Levy-Lahad E, Zevin S, Hadas-Halpern I, Bar- Ziv Y, et al. Replacement therapy with imiglucerase for type 1 Gaucher's disease. Lancet 1995;345:1479-80.
  7. Weinreb NJ, Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, et al. Effectiveness of enzyme replacement therapy in 1,028 patients with Type 1 Gaucher disease after 2-5 years of treatment: a report from the Gaucher registry. Am J Med 2002;113:112-9.
  8. Barton NW, Brady RO, Dambrosia JM, Di Bisceglie AM, Doppelt SH, Hill SC, et al. Replacement therapy for inherited enzyme deficiency: macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med 1991;324:1464-70.
  9. Rosenthal DI, Doppelt SH, Mankin HJ, Dambrosia JM, Xavier RJ, McKusick KA, et al. Enzyme replacement therapy for Gaucher disease: skeletal responses to macrophage-targeted glucocerebrosidase. Pediatrics 1995;96:629-37.
  10. Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, Pastores G, et al. The Gaucher Registry: demographics and disease characteristics of 1,698 patients with Gaucher disease. Arch Intern Med 2000;160:2835-43.
  11. Kaplan P, Mazur A, Manor O, Charrow J, Esplin J, Gribble TJ, et al. Acceleration of retarded growth in children with Gaucher disease after treatment with alglucerase. J Pediatr 1996;129:149-53.
  12. Charrow J, Esplin JA, Gribble TJ, Kaplan P, Kolodny EH, Pastores GM, et al. Gaucher disease: recommendations on diagnosis, evaluation, and monitoring. Arch Intern Med 1998;158:1754-60.
  13. Beutler E, Saven A. Misuse of marrow examination in the diagnosis of Gaucher disease. Blood 1990;76:646-8.
  14. Beutler E, Kuhl W, Trinidad F, Teplitz RL, Nadler HL. Beta- glucosidase activity in fibroblasts from homozygotes and heterozygotes for Gaucher disease. Am J Hum Genet 1971;23:62-8.
  15. Grabowski GA, Saal HM, Wenstrup RJ, Barton NW. Gaucher disease: a prototype for molecular medicine. Crit Rev Oncol Hematol 1996;23:25-55.
  16. Alterini R, Rigacci L, Stefanacci S. Pseudo-Gaucher cells in the bone marrow of a patient with centrocytic nodular non-Hodgkin's lymphoma. Haematologica 1996;81:282-3.
  17. Kattlove HE, Williams JC, Gaynor E, Spivack M, Bradley RM, Brady RO. Gaucher cells in chronic myelocytic leukemia: an acquired abnormality. Blood 1969;3:379-90.
  18. Sorge J, West C, Westwood B, Beutler E. Molecular cloning and nucleotide sequence of human glucocerebrosidase cDNA. Proc Natl Acad Sci U S A 1985;82:7289-93.
  19. Tsuji S, Choudary PV, Martin BM, Winfield S, Barranger JA, Ginns EI. Nucleotide sequence of cDNA containing the complete coding sequence for human lysosomal glucocerebrosidase. J Biol Chem 1986;261:50-3.
  20. Horowitz M, Wilder S, Horowitz Z, Reiner O, Gelbart T, Beutler E. The human glucocerebrosidase gene and pseudogene: structure and evolution. Genomics 1989;4:87-96.
  21. Koprivica V, Stone DL, Park JK, Callahan M, Frisch A, Cohen IJ, et al. Analysis and classification of 304 mutant alleles in patients with type 1 and type 3 Gaucher disease. Am J Hum Genet 2000;66:1777-86.
  22. Barranger JA, Rice E, Sakallah SA, Sansieri C, Mifflin TE, Cooper DL. Enzymatic and molecular diagnosis of Gaucher disease. Clin Lab Med 1995; 15:899-913.
  23. Horowitz M, Zimran A. Mutations causing Gaucher disease. Hum Mutat 1994;3:1-11.
  24. Zimran A, Sorge J, Gross E, Kubitz M, West C, Beutler E. Prediction of severity of Gaucher's disease by identification of mutations at DNA level. Lancet II 1989:349-52.
  25. Sibille A, Eng CM, Kim SJ, Pastores G, Grabowski GA. Phenotype/ genotype correlations in Gaucher disease type 1: clinical and therapeutic implications. Am J Hum Genet 1993;52:1094-101.
  26. Grabowski GA. Gaucher disease: enzymology, genetics, and treatment. In: Harris H, Hirschhorn K, eds. Advances in human genetics. New York: Plenum Press; 1993. p. 377-441.
  27. Kolodny EH, Firon N, Eyal N, Horowitz M. Mutation analysis of Ashkenazi Jewish family with Gaucher disease in three successive generations. Am J Med Genet 1990;36:467-72.
  28. Erikson A. Gaucher disease-Norrbottnian type (III). Neuropaediatric and neurobiological aspects of clinical patterns and treatment. Acta Paediatr Scand Suppl 1986;326:1-42.
  29. Grewal RP, Doppelt SH, Thompson MA, Katz D, Brady RO, Barton NW. Neurologic complications of nonneuronopathic Gaucher's disease. Arch Neurol 1991;48:1271-2.
  30. Erikson A, Wahlberg I. Gaucher disease-Norrbottnian type. Ocular abnormalities. Acta Ophthalmol (Copenh) 1985;63:221-5.
  31. Vellodi A, Bembi B, de Villemeur TB, Collin-Histed T, Erikson A, Mengel E, et al. Neuronopathic Gaucher Disease Task Force of the European Working Group on Gaucher Disease. Management of neuronopathic Gaucher disease: a European consensus. J Inherit Metab Dis 2001;24: 319-327.
  32. Parker RI, Barton NW, Read EJ, Brady RO. Hematologic improvement in a patient with Gaucher disease on long-term enzyme replacement therapy: evidence for decreased splenic sequestration and improved red blood cell survival. Am J Hematol 1991;38:130-7.
  33. Pastores GM, Sibille AR, Grabowski GA. Enzyme therapy in Gaucher disease type 1: dosage, efficacy and adverse effects in 33 patients treated for 6 to 24 months. Blood 1993;82:408-16.
  34. Beutler E, Grabowski GA. Gaucher disease. In: Scriver CR, Beaudet AL, Sly WS, et al, eds. The metabolic and molecular basis of inherited disease. 8th ed. New York: McGraw-Hill International Book Co; 2001. p. 3635-68.
  35. Hollak CE, van Weely S, van Oers MH, Aerts JM. Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J Clin Invest 1994;93:1288-92.
  36. Zimran A, Kay A, Gelbart T, Garver P, Thurston D, Saven A, et al. Gaucher disease. Clinical, laboratory, radiologic, and genetic features of 53 patients. Medicine 1992;71:337-53.
  37. Lee RE. The pathology of Gaucher disease. In: Desnick RJ, Gatt S, Grabowski GA, eds. Gaucher disease: a century of delineation and research. New York: Alan R. Liss, Inc; 1982. p. 177-217.
  38. James SP, Stromeyer FW, Chang C, Barranger JA. Liver abnormalities in patients with Gaucher disease. Gastroenterology 1981;80:126-33.
  39. Glass RBJ, Poznanski AK, Young S, Urban MA. Gaucher disease of the liver: CT appearance. Pediatr Radiol 1987;17:417-8.
  40. Hill SC, Damaska BM, Ling A, Patterson K, Di Bisceglie AM, Brady RO, et al. Gaucher disease: abdominal MR imaging findings in 46 patients. Radiology 1992;184:561-6.
  41. Ludwig J. Current methods of autopsy practice. Philadelphia: WB Saunders; 1979.
  42. Elstein D, Hadas-Halpern I, Azuri Y, Abrahamov A, Bar-Ziv, Zimran A. Accuracy of ultrasonography in assessing spleen and liver size in patients with Gaucher disease. Comparison to computed tomographic measurements. J Ultrasound Med 1997;16:209-11.
  43. Glenn D, Thurston D, Garver P, Beutler E. Comparison of magnetic resonance imaging and ultrasound in evaluating liver size in Gaucher patients. Acta Haematol 1994;92:187-9.
  44. Mankin HJ, Doppelt SH, Rosenberg AE, Barranger JA. Metabolic bone disease in patients with Gaucher's disease. In: Avioli LV, Krane SM, eds. Metabolic bone disease. 2nd ed. Philadelphia (PA): WB Saunders; 1990. p. 730-52.
  45. Pastores GM, Einhorn TA. Skeletal complications of Gaucher disease: pathophysiology, evaluation, and treatment. Semin Hematol 1995;32(3, Suppl 1):20-7.
  46. Stowens DW, Teitelbaum SL, Kahn AJ, Barranger JA. Skeletal complications of Gaucher disease. Medicine 1985;64:310-22.
  47. Belmatoug N, Bilette de Villemeur for the Comite d'Evaluation du Traitement par la Ceredase. Skeletal response to enzyme replacement therapy of type 1 Gaucher disease: a preliminary report of the French experience. Semin Hematol 1995;32(3, Suppl 1):33-8.
  48. Hermann G, Shapiro RS, Abdelwahab IF, Grabowski G. MR imaging in adults with Gaucher disease type I: evaluation of marrow involvement and disease activity. Skeletal Radiol 1993;22:247-51.
  49. Rademakers RP. Radiologic evaluation of Gaucher bone disease. Semin Hematol 1995;32(3, Suppl 1):14-9.
  50. Rosenthal DI, Scott JA, Barranger J, Mankin HJ, Saini S, Brady TJ, et al. Evaluation of Gaucher disease using magnetic resonance imaging. J Bone Joint Surg 1986;68:802-8.
  51. Waitches G, Zawin JK, Poznanski AK. Sequence and rate of bone marrow conversion in the femora of children as seen on MR imaging: are accepted standards accurate? AJR Am J Roentgenol 1994;162:1399-406.
  52. Rosenthal DI, Barton NW, McKusick KA, Rosen BR, Hill SC, Castronovo FP, et al. Quantitative imaging of Gaucher disease. Radiology 1992;185:841-5.
  53. Pastores GM, Wallenstein S, Desnick RJ, Luckey MM. Bone density in type I Gaucher disease. J Bone Miner Res 1996;11:1801-7.
  54. Feuer EJ, Wun LM. DevCan, probability of developing or dying of cancer software, Version 4.1. Bethesda, Maryland: National Cancer Institute; 2001.
  55. Upton AC. Health effects of exposure to low levels of ionizing radiation. National Research Council Committee on the Biological Effects of Ionizing Radiation. Washington (DC): National Academy Press; 1990. p. 175.
  56. Selman J. The fundamentals of x-ray and radium physics. 8th ed. Springfield (IL): Charles C. Thomas Publisher; 1994.
  57. Johns HE, Cunningham JR. The physics of radiology. 3rd ed. Springfield (IL): Charles C. Thomas Publisher; 1969. p. 709-10.
  58. NCRP Report 116. Limitation of exposure to ionizing radiation. Bethesda, Maryland: National Council on Radiation Protection and Measurements; 1993. p. 23.
  59. American Academy of Pediatrics, Committee on Drugs, Section on Anesthesiology. Guidelines for the elective use of conscious sedation, deep sedation, and general anesthesia in pediatric patients. Pediatrics 1985;76: 317-21.
  60. American Academy of Pediatrics, Committee on Drugs, Section on Anesthesiology. Guidelines for monitoring and management of pediatric patients during and after sedation for diagnostic and therapeutic procedures. Pediatrics 1992;89:1110-5.
  61. Practice guidelines for sedation and analgesia by non-anesthesiologists. A report by the American Society of Anesthesiologists Task Force on Sedation and Analgesia by Non-anesthesiologists. Anesthesiology 1996; 84:459-71.
  62. Poe SS, Nolan MT, Dang D, Schauble J, Oechsle DG, Kress L, et al. Ensuring the safety of patients receiving sedation for procedures: evaluation of clinical practice guidelines. Joint Comm J Qual Improv 2001;27:28-41.
  63. Joint Commission on Accreditation of Healthcare Organizations. Revisions to anesthesia care standards: comprehensive accreditation manual for hospitals. Oakbrook Terrace (IL): Joint Commission on Accreditation of Healthcare Organizations, Department of Publications; 2001.
  64. Hoffman GM, Nowakowski R, Troshynski TJ, Berens RJ, Weisman SJ. Risk reduction in pediatric procedural sedation by application of an American Academy of Pediatrics/American Society of Anesthesiologists Process Model. Pediatrics 2002;109:236-43.
  65. Van Weely S, Van Leeuwen MB, Jansen ID, De Bruijn MA, Brouwer- Kelder EM, Schram AW, et al. Clinical phenotype of Gaucher disease in relation to properties of mutant glucocerebrosidase in cultured fibroblasts. Biochim Biophys Acta 1991;1096:301-11.
  66. Barton NW, Furbish FS, Murray GJ, Garfield M, Brady RO. Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease. Proc Natl Acad Sci U S A 1990;87:1913-6.
  67. Fallet S, Grace ME, Sibille A, Mendelson DS, Shapiro RS, Hermann G, et al. Enzyme augmentation in moderate to life-threatening Gaucher disease. Pediatr Res 1992;31:496-502.
  68. Verderese CL, Graham OC, Holder-McShane CA, Harnett NE, Barton NW. Gaucher's disease: a pilot study of the symptomatic responses to enzyme replacement therapy. J Neurosci Nurs 1993;25:296-301.
  69. Barton NW, Brady RO, Dambrosia JM, Doppelt SH, Hill SC, Holder CA, et al. Dose-dependent responses to macrophage-targeted glucocerebro- sidase in a child with Gaucher Disease. J Pediatr 1992;120(2):277-80.
  70. Zaizov R, Frish A, Cohen IJ. Lower-dose, high-frequency enzyme replacement therapy in children with type 1 Gaucher disease: experience at the Schneider Children's Medical Center of Israel. Semin Hematol 1995;32(3, Suppl 1):39-44.
  71. Migita M, Fukunaga Y, Ueda T, Watanabe A, Morita T, Yamamoto M. Progression of bone disease without deterioration of hematological parameters in a child with Gaucher disease during low-dose glucocerebroside therapy. J Nippon Med Sch 1994;61:633-7.
  72. International Collaborative Gaucher Group (ICGG) Gaucher Registry database.